Last reviewed · How we verify
Intravenous placebo before endovascular thrombectomy
Intravenous placebo serves as a control intervention in a clinical trial comparing the efficacy and safety of endovascular thrombectomy with and without placebo pretreatment.
Intravenous placebo serves as a control intervention in a clinical trial comparing the efficacy and safety of endovascular thrombectomy with and without placebo pretreatment. Used for Acute ischemic stroke eligible for endovascular thrombectomy (Phase 3 trial comparator).
At a glance
| Generic name | Intravenous placebo before endovascular thrombectomy |
|---|---|
| Sponsor | General Hospital of Shenyang Military Region |
| Modality | Small molecule |
| Therapeutic area | Neurology / Stroke |
| Phase | Phase 3 |
Mechanism of action
This is a placebo comparator used in a Phase 3 randomized controlled trial to establish the baseline effect of endovascular thrombectomy alone versus thrombectomy preceded by intravenous placebo administration. Placebo allows researchers to isolate the true therapeutic benefit of the mechanical thrombectomy procedure by controlling for patient expectations and natural disease progression in acute ischemic stroke.
Approved indications
- Acute ischemic stroke eligible for endovascular thrombectomy (Phase 3 trial comparator)
Common side effects
Key clinical trials
- Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke (PHASE2)
- Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) (PHASE3)
- Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window (PHASE3)
- Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban (PHASE3)
- Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke (PHASE3)
- Methylprednisolone for Stroke With Large Infarct Core and Post-stroke Lymphocytopenia (PHASE3)
- Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: